United Therapeutics Corporation - Common Stock (NQ:UTHR)

545.46 +5.41 (+1.00%)

Streaming Delayed Price Updated: 11:43 AM EDT, Jun 3, 2026 Add to My Watchlist

Price and Volume

Volume	77,600
Open	543.50
Bid (Size)	544.26 (120)
Ask (Size)	546.66 (160)
Prev. Close	540.05
Today's Range	541.10 - 552.00
52wk Range	272.12 - 609.35
Shares Outstanding	44,891,523
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

1 Cash-Producing Stock with Exciting Potential and 2 We Ignore

Today 0:33 EDT

Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it eff...

Via StockStory

What to Know About This Fund's $5.4 Million Ultragenyx Purchase as Shares Slip 30% in One Year ↗

May 30, 2026

Ultragenyx develops therapies for rare genetic diseases, with a portfolio spanning approved biologics and a pipeline of gene therapies.

Via The Motley Fool

Performance

YTD	+9.8%	+9.8%
1 Month	-6.2%	-6.2%
3 Month	+9.4%	+9.4%
6 Month	+15.0%	+15.0%
1 Year	+67.6%	+67.6%

More News

2 Mid-Cap Stocks on Our Buy List and 1 We Turn Down

May 29, 2026

Via StockStory

United Therapeutics (NASDAQ:UTHR) Shares Dip After Q1 2026 Earnings Miss ↗

May 06, 2026

Via Chartmill

United Therapeutics Corporation to Present at the Jefferies Global Healthcare Conference

May 27, 2026

From United Therapeutics Corporation

Via Business Wire

United Therapeutics Corporation Announces TETON-1 Study of Tyvaso Published in The New England Journal of Medicine and Presented at ATS 2026

May 18, 2026

From United Therapeutics Corporation

Via Business Wire

United Therapeutics Corporation Announces ADVANCE OUTCOMES Study of Ralinepag Presented at ATS 2026

May 17, 2026

From United Therapeutics Corporation

Via Business Wire

United Therapeutics Corporation Announces FDA Clearance to Proceed with UHeart Xenotransplantation Clinical Trial

May 15, 2026

From United Therapeutics Corporation

Via Business Wire

5 Insightful Analyst Questions From United Therapeutics’s Q1 Earnings Call

May 13, 2026

Via StockStory

United Therapeutics Corporation to Present at the RBC Capital Markets Global Healthcare Conference

May 12, 2026

From United Therapeutics Corporation

Via Business Wire

United Therapeutics Corporation Presents New Data from TETON-1, ADVANCE OUTCOMES, and Additional Research in Pulmonary Hypertension and Pulmonary Fibrosis at ATS 2026

May 11, 2026

From United Therapeutics Corporation

Via Business Wire

UTHR Q1 Deep Dive: Pipeline Advances and Product Launches Dominate Outlook

May 07, 2026

Via StockStory

UTHR Q1 2026 Earnings Transcript ↗

May 06, 2026

Via The Motley Fool

United Therapeutics (NASDAQ:UTHR) Reports Sales Below Analyst Estimates In Q1 CY2026 Earnings

May 06, 2026

Via StockStory

United Therapeutics Corporation Reports First Quarter 2026 Financial Results

May 06, 2026

From United Therapeutics Corporation

Via Business Wire

MannKind Announces Ralinepag Dry Powder Inhalation (DPI) Program to be Pursued for Pulmonary Hypertension and Fibrotic Lung Diseases

May 06, 2026

From MannKind

Via GlobeNewswire

United Therapeutics (UTHR) Q1 Earnings Report Preview: What To Look For

May 04, 2026

Via StockStory

United Therapeutics Corporation Announces Retirement of Professor Raymond Dwek, C.B.E., F.R.S., From Its Board of Directors

April 29, 2026

From United Therapeutics Corporation

Via Business Wire

The eVTOL Era is Beginning With Uber and Joby Aviation: What Investors Need to Know ↗

April 29, 2026

Via The Motley Fool

United Therapeutics Corporation to Report First Quarter 2026 Financial Results Before Market Open on Wednesday, May 6, 2026

April 22, 2026

From United Therapeutics Corporation

Via Business Wire

UTHR Q4 2025 Earnings Transcript ↗

April 21, 2026

Via The Motley Fool

United Therapeutics Corporation Presents New Data Spanning Pulmonary Hypertension Treatment, Lung Donor Expansion, and Xenotransplantation at ISHLT 2026

April 20, 2026

From United Therapeutics Corporation

Via Business Wire

3 Reasons Investors Love United Therapeutics (UTHR)

April 17, 2026

Via StockStory

United Therapeutics Receives FDA Regenerative Medicine Advanced Therapy Designation for miroliverELAP® for Treatment of Acute Liver Failure

April 08, 2026

From United Therapeutics Corporation

Via Business Wire

3 Market-Beating Stocks for Long-Term Investors

April 07, 2026

Via StockStory

Frequently Asked Questions

Is United Therapeutics Corporation - Common Stock publicly traded?

Yes, United Therapeutics Corporation - Common Stock is publicly traded.

What exchange does United Therapeutics Corporation - Common Stock trade on?

United Therapeutics Corporation - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for United Therapeutics Corporation - Common Stock?

The ticker symbol for United Therapeutics Corporation - Common Stock is UTHR on the Nasdaq Stock Market

What is the current price of United Therapeutics Corporation - Common Stock?

The current price of United Therapeutics Corporation - Common Stock is 545.46

When was United Therapeutics Corporation - Common Stock last traded?

The last trade of United Therapeutics Corporation - Common Stock was at 06/03/26 11:43 AM ET

What is the market capitalization of United Therapeutics Corporation - Common Stock?

The market capitalization of United Therapeutics Corporation - Common Stock is 24.49B

How many shares of United Therapeutics Corporation - Common Stock are outstanding?

United Therapeutics Corporation - Common Stock has 24B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.